Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance
PROVIDERS
Providers Acalabrutinib

Acalabrutinib

Trade Name

ACP-196

Class

BTK Inhibitor

Cancer Indication

FDA has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.